Obesity Today—June 2, 2026

This week’s Obesity therapeutics update highlights late-stage clinical progress, early pipeline advances, upcoming data presentations, and evolving reimbursement and access policies across major markets.

In this Newsletter

Dive deeper

🧬 Kailera advances obesity pipeline [1] [US • 26 May 2026]

https://investors.kailera.com/news-releases/news-release-details/kailera-reports-first-quarter-2026-financial-results-and
Context: Kailera (KLRA) reported Q1 2026 results and updates across ribupatide, KAI-7535, and KAI-4729.
Key point: Ribupatide injection entered global Phase 3, oral ribupatide showed Phase 2 obesity data, and KAI-7535 met a Phase 3 T2D endpoint in China.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Celltrion starts CT-G32 toxicology [2] [South Korea • 29 May 2026]

https://www.celltrion.com/en-us/company/media-center/press-release/4789
Context: Celltrion began primate toxicology for CT-G32, a quadruple-action obesity candidate involving GLP-1 and three other targets.
Key point: The company targets IND submission in the first half of next year and is evaluating broader metabolic indications.
Implication: Signals pipeline investment and modality expansion.

💊 Kalohexis doses 710GO Phase 1 [3] [Australia • 29 May 2026]

https://www.clinicaltrialsarena.com/news/kalohexis-doses-first-patients-710go-trial/
Context: Kalohexis dosed first participants in a Phase 1 first-in-human trial of 710GO, an oral MC3R/MC4R agonist.
Key point: The trial will assess pharmacodynamics, pharmacokinetics, preliminary efficacy, safety, and tolerability in obese or healthy overweight volunteers.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 Wegovy Pill leads Foundayo in early uptake [4] [US • 27 May 2026]

https://www.spherixglobalinsights.com/eli-lillys-oral-glp-1-foundation-trails-novo-nordisks-wegovy-pill-in-early-obesity-launch-uptake-according-to-spherix-global-insights/
Context: Spherix Global Insights compared early physician uptake of Wegovy Pill (Novo Nordisk; oral semaglutide) and Foundayo (Eli Lilly; orforglipron).
Key point: Surveyed physicians reported stronger first-month prescribing momentum for Wegovy Pill than Foundayo.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

⚖️ InBody linked to obesity management demand [5] [South Korea • 28 May 2026]

https://en.sedaily.com/finance/2026/05/28/inbody-set-to-benefit-from-expanding-obesity-management
Context: Mirae Asset Securities linked GLP-1 commercialization to rising demand for body composition analysis.
Key point: InBody may benefit as clinics track fat mass, skeletal muscle mass, and muscle preservation during obesity treatment.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧫 Roche sets ADA obesity data slate [6] [US • 01 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/01/3303993/0/en/roche-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-association-s-2026-scientific-sessions.html
Context: Roche will present ADA 2026 data for enicepatide (CT-388; GLP-1/GIP agonist) and petrelintide (amylin analog).
Key point: Roche says both assets are moving toward Phase 3, with a Phase 2 multi-arm combination trial planned for mid-2026.
Implication: Signals pipeline investment and modality expansion.

📊 Innogen to present ENLIGHT Phase 2b [7] [US • 01 Jun 2026]

https://www.biospace.com/press-releases/innogen-to-present-phase-iib-enlight-study-results-for-efsubaglutide-alfa-at-the-2026-ada-scientific-sessions
Context: Innogen will present Phase 2b ENLIGHT data for efsubaglutide alfa in overweight and obesity at ADA 2026.
Key point: The randomized Phase 2b study in Chinese adults without diabetes met its primary endpoint and showed dose-related weight loss.
Implication: May influence prescriber choice and payer reviews pending full data.

🇫🇷 France to reimburse Wegovy and Mounjaro [8] [France • 28 May 2026]

https://www.scmp.com/news/world/europe/article/3354245/eu-picks-tungsten-rare-earths-gallium-first-critical-mineral-stockpile
Context: France will reimburse Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) for severely obese patients from mid-June.
Key point: Reimbursement will target patients with BMI-based eligibility and relevant comorbidity criteria.
Implication: May expand screening, initiation, and follow-up at scale.

🇰🇷 Korea MFDS plans GLP-1 controls [9] [South Korea • 27 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31799
Context: South Korea’s MFDS is moving to designate GLP-1 obesity drugs as medications with abuse concerns.
Key point: The designation would tighten prescription, use, advertising, and distribution standards amid cosmetic-use concerns.
Implication: Introduces competition that may affect pricing and formulary access.

🚫 Korea targets Wegovy and Mounjaro misuse [10] [South Korea • 27 May 2026]

https://www.koreaherald.com/article/10757142
Context: South Korea is targeting prescription loopholes and overseas purchases of Wegovy and Mounjaro.
Key point: The planned controls include prescription requirements, packaging warnings, and customs or online sales enforcement.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Oral and injectable obesity pipelines are diversifying across incretin, amylin, melanocortin, and multi-agonist mechanisms.
ADA 2026 is becoming a key readout venue for Roche, Innogen, Kailera, and other obesity programs.
Regulators and payers are moving from product availability to access control, reimbursement, and misuse prevention.
Body composition monitoring is becoming more visible as muscle preservation becomes part of obesity care.
South Korea and France highlight a broader policy split: tighter safety controls versus expanded reimbursement.

📚 View the full Obesity archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What is Kailera advancing in obesity?

Kailera is advancing ribupatide injection, oral ribupatide, KAI-7535, and KAI-4729 across obesity and related metabolic indications. The company reported Phase 3 starts, topline data, and planned clinical milestones. [1]

What makes Celltrion’s CT-G32 notable?

CT-G32 is described by Celltrion as a quadruple-action obesity candidate involving GLP-1 and three other targets. It is still preclinical, with primate toxicology underway and IND submission targeted for next year. [2]

How is Kalohexis 710GO differentiated?

710GO is an oral MC3R/MC4R agonist designed to activate the melanocortin system. The Phase 1 trial is early-stage, so efficacy and safety remain to be established in humans. [3]

What will Roche present at ADA 2026?

Roche will present data for enicepatide (CT-388) and petrelintide, including Phase 2 obesity readouts. Roche also said both assets are moving into Phase 3 development. [6]

What changed in France for Wegovy and Mounjaro?

France plans reimbursement for Wegovy and Mounjaro in severely obese patients from mid-June, using BMI and comorbidity criteria. This could broaden access for eligible patients. [8]

Why is South Korea tightening GLP-1 controls?

South Korean authorities cited misuse for cosmetic weight loss, overseas purchasing, and product safety concerns. Planned controls target prescribing, packaging warnings, online sales, and customs enforcement. [9], [10]

Entities / Keywords

Kailera Therapeutics, KLRA, ribupatide, KAI-9531, KAI-9531-T, KAI-7535, HRS-7535, KAI-4729, HRS-4729, KaiNETIC
Celltrion, CT-G32, GLP-1, quadruple-action obesity candidate, Scohia Pharma
Kalohexis, 710GO, MC3R, MC4R, melanocortin agonist
Novo Nordisk, Wegovy Pill, oral semaglutide, Wegovy
Eli Lilly, Foundayo, orforglipron, Mounjaro
InBody, body composition analyzer, skeletal muscle mass, fat mass
Roche, enicepatide, CT-388, petrelintide, ZUPREME-1, ZUPREME-2
Innogen, efsubaglutide alfa, ENLIGHT, ADA 2026
MFDS, Ministry of Food and Drug Safety, South Korea GLP-1 controls
France reimbursement, anti-obesity drugs, BMI eligibility